BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reig M, da Fonseca LG, Faivre S. New trials and results in systemic treatment of HCC. J Hepatol 2018;69:525-33. [PMID: 29653122 DOI: 10.1016/j.jhep.2018.03.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Heverhagen JT, Kudrnová S. Subcentimeter Hepatocellular Carcinoma: A New Paradigm for Treatment with Percutaneous Radiofrequency Ablation? Radiology 2018;288:887-8. [PMID: 29916779 DOI: 10.1148/radiol.2018180977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Yang WJ, Sun YF, Jin AL, Lv LH, Zhu J, Wang BL, Zhou Y, Zhang CY, Wang H, Hu B, Wang PX, Te L, Pan BS, Zhou J, Fan J, Yang XR, Guo W. BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. Cell Death Dis 2020;11:895. [PMID: 33093445 DOI: 10.1038/s41419-020-03115-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Liu T, Wu H, Qi J, Qin C, Zhu Q. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma. Cancer Med 2020;9:7440-52. [PMID: 32815653 DOI: 10.1002/cam4.3406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Dong X, Feng M, Yang H, Liu H, Guo H, Gao X, Liu Y, Liu R, Zhang N, Chen R, Kong R. Rictor promotes cell migration and actin polymerization through regulating ABLIM1 phosphorylation in Hepatocellular Carcinoma. Int J Biol Sci 2020;16:2835-52. [PMID: 33061800 DOI: 10.7150/ijbs.46285] [Reference Citation Analysis]
5 Liao X, Bu Y, Jia Q. Traditional Chinese medicine as supportive care for the management of liver cancer: Past, present, and future. Genes Dis 2020;7:370-9. [PMID: 32884991 DOI: 10.1016/j.gendis.2019.10.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
6 Marta GN, da Fonseca LG, Braghiroli MI, Moura F, Hoff PM, Sabbaga J. Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma. Clinics (Sao Paulo) 2021;76:e2498. [PMID: 33503195 DOI: 10.6061/clinics/2021/e2498] [Reference Citation Analysis]
7 Lu Y, Wang Y, He Y, Pan J, Jin Y, Zheng L, Huang Y, Li Y, Liu W. Aidi injection altered the activity of CYP2D4, CYP1A2, CYP2C19, CYP3A2, CYP2E1 and CYP2C11 in normal and diethylnitrosamine-induced hepatocellular carcinoma in rats. J Ethnopharmacol 2021;:114930. [PMID: 34952190 DOI: 10.1016/j.jep.2021.114930] [Reference Citation Analysis]
8 Pestana RC, Hassan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, Chang P, Raghav K, Morris J, Wolff RA, Rashid A, Amin HM, Kaseb A. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget. 2018;9:37721-37732. [PMID: 30701027 DOI: 10.18632/oncotarget.26507] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
9 Choi SH, Cho KJ, Yun SH, Jin B, Lee HY, Ro SW, Kim DY, Ahn SH, Han KH, Park JY. HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines. J Cancer 2020;11:2442-52. [PMID: 32201515 DOI: 10.7150/jca.39380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ferrarese A, Sciarrone SS, Pellone M, Shalaby S, Battistella S, Zanetto A, Germani G, Russo FP, Senzolo M, Burra P, Gambato M. Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. Minerva Gastroenterol 2021;67. [DOI: 10.23736/s2724-5985.20.02775-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Díaz-gonzález Á, Sanduzzi-zamparelli M, Sapena V, Torres F, Llarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2019;49:482-91. [DOI: 10.1111/apt.15088] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
12 Zhang Y, Liu X, Liu L, Chen J, Hu Q, Shen S, Zhou Y, Chen S, Xue C, Cui G, Yu Z. Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma. Dis Markers 2020;2020:2514090. [PMID: 32399086 DOI: 10.1155/2020/2514090] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
13 Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333 [DOI: 10.12998/wjcc.v10.i11.3321] [Reference Citation Analysis]
14 Liu Z, Wang J, Yuan H, Liu L, Bu Y, Zhao M, Yang G, Feng J, Liu Y, Li J, He Q, Zhang X. IFN-α2b inhibits the ethanol enriched-HBV cccDNA through blocking a positive feedback loop of HBx/MSL2/cccDNA/HBV/HBx in liver. Biochem Biophys Res Commun 2020;527:76-82. [PMID: 32446394 DOI: 10.1016/j.bbrc.2020.04.057] [Reference Citation Analysis]
15 Yao M, Sai W, Zheng W, Wang L, Dong Z, Yao D. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth. Curr Med Chem 2020;27:3290-301. [PMID: 31232234 DOI: 10.2174/0929867326666190624161158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Qu N, Bo X, Li B, Ma L, Wang F, Zheng Q, Xiao X, Huang F, Shi Y, Zhang X. Role of N6-Methyladenosine (m6A) Methylation Regulators in Hepatocellular Carcinoma. Front Oncol 2021;11:755206. [PMID: 34692544 DOI: 10.3389/fonc.2021.755206] [Reference Citation Analysis]
17 Liu Z, Lu Z, Jing R, Zuo B, Gao X, Han G, Qi H, Wu L, Liu Y, Yin H. Alarmin augments the antitumor immunity of lentiviral vaccine in ectopic, orthotopic and autochthonous hepatocellular carcinoma mice. Theranostics 2019;9:4006-18. [PMID: 31281528 DOI: 10.7150/thno.32720] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
18 Da Fonseca LG, Leonardi PC, Hashizume PH, Sansone F, Saud LR, Carrilho FJ, Herman P. A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes. Clin Exp Hepatol 2022;8:42-8. [PMID: 35415264 DOI: 10.5114/ceh.2022.114297] [Reference Citation Analysis]
19 Wu M, Liu Z, Li X, Zhang A, Lin D, Li N. Analysis of potential key genes in very early hepatocellular carcinoma. World J Surg Oncol 2019;17:77. [PMID: 31043166 DOI: 10.1186/s12957-019-1616-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
20 Weiz G, Molejon MI, Malvicini M, Sukowati CHC, Tiribelli C, Mazzolini G, Breccia JD. Glycosylated 4-methylumbelliferone as a targeted therapy for hepatocellular carcinoma. Liver Int 2021. [PMID: 34800352 DOI: 10.1111/liv.15084] [Reference Citation Analysis]
21 Wei S, Liu W, Sun N, Wu Y, Song H, Wang C, Wang S, Zou R, Lin L, Zeng K, Zhou B, Wang M, Luan R, Yang F, Zhao Y. MOF upregulates the estrogen receptor α signaling pathway by its acetylase activity in hepatocellular carcinoma. Cancer Sci 2021;112:1865-77. [PMID: 33544437 DOI: 10.1111/cas.14836] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wu L, Li H, Chen S, Wu X, Chen X, Wang F. Catalpol inhibits the proliferation, migration and metastasis of HCC cells by regulating miR‑140‑5p expression. Mol Med Rep 2021;23:29. [PMID: 33179108 DOI: 10.3892/mmr.2020.11667] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
23 Wang J, Sun J, Zhang N, Yang R, Li H, Zhang Y, Chen K, Kong D. PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway. Life Sci 2019;219:182-9. [PMID: 30630006 DOI: 10.1016/j.lfs.2018.12.054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
24 Zhong L, Hou C, Zhang L, Zhao J, Li F, Li W. Synthesis of deuterium-enriched sorafenib derivatives and evaluation of their biological activities. Mol Divers 2019;23:341-50. [DOI: 10.1007/s11030-018-9875-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Bayo J, Fiore EJ, Dominguez LM, Real A, Malvicini M, Rizzo M, Atorrasagasti C, García MG, Argemi J, Martinez ED, Mazzolini GD. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets. J Hepatol 2019;71:78-90. [PMID: 30880225 DOI: 10.1016/j.jhep.2019.03.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
26 Liu Y, Feng J, Sun M, Yang G, Yuan H, Wang Y, Bu Y, Zhao M, Zhang S, Zhang X. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett. 2019;454:158-170. [PMID: 30981758 DOI: 10.1016/j.canlet.2019.04.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 9.7] [Reference Citation Analysis]
27 Myojin Y, Hikita H, Sugiyama M, Sasaki Y, Fukumoto K, Sakane S, Makino Y, Takemura N, Yamada R, Shigekawa M, Kodama T, Sakamori R, Kobayashi S, Tatsumi T, Suemizu H, Eguchi H, Kokudo N, Mizokami M, Takehara T. Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production. Gastroenterology 2021;160:1741-1754.e16. [PMID: 33346004 DOI: 10.1053/j.gastro.2020.12.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
28 Wang S, Deng Y, Yu X, Zhang XW, Huo CL, Sun ZG, Chang H. Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram. Sci Rep 2021;11:13814. [PMID: 34226605 DOI: 10.1038/s41598-021-93289-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Huang X, Zhu S, Zhang K, Tan W, Chen Y, Shang C. High Expression of Long Non-Coding RNA TMCO1-AS1 is Associated With Poor Prognosis of Hepatocellular Carcinoma. Front Mol Biosci 2022;9:814058. [DOI: 10.3389/fmolb.2022.814058] [Reference Citation Analysis]
30 Javan H, Dayyani F, Abi-Jaoudeh N. Therapy in Advanced Hepatocellular Carcinoma. Semin Intervent Radiol 2020;37:466-74. [PMID: 33328702 DOI: 10.1055/s-0040-1719187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Jiang L, Wu CL, Wu JZ, Yang X, Wang HL, Li GJ. Microarray-based measurement of microRNA-449c-5p levels in hepatocellular carcinoma and bioinformatic analysis of potential signaling pathways. Pathol Res Pract 2019;215:68-81. [PMID: 30389318 DOI: 10.1016/j.prp.2018.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Sanduzzi-Zamparelli M, Díaz-Gonzalez Á, Reig M. New Systemic Treatments in Advanced Hepatocellular Carcinoma. Liver Transpl 2019;25:311-22. [PMID: 30317696 DOI: 10.1002/lt.25354] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
33 Moser M, Radu IP, Dufour JF. Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib. JGH Open 2021;5:864-70. [PMID: 34386593 DOI: 10.1002/jgh3.12533] [Reference Citation Analysis]
34 Hu Q, Ma X, Li C, Zhou C, Chen J, Gu X. Downregulation of THRSP Promotes Hepatocellular Carcinoma Progression by Triggering ZEB1 Transcription in an ERK-dependent Manner. J Cancer 2021;12:4247-56. [PMID: 34093825 DOI: 10.7150/jca.51657] [Reference Citation Analysis]
35 Zhang L, Luo B, Dang Y, He R, Chen G, Peng Z, Feng Z. The clinical significance of endothelin receptor type B in hepatocellular carcinoma and its potential molecular mechanism. Experimental and Molecular Pathology 2019;107:141-57. [DOI: 10.1016/j.yexmp.2019.02.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
36 Guo Q, Yu DY, Yang ZF, Liu DY, Cao HQ, Liao XW. IGFBP2 upregulates ZEB1 expression and promotes hepatocellular carcinoma progression through NF-κB signaling pathway. Dig Liver Dis 2020;52:573-81. [PMID: 31818638 DOI: 10.1016/j.dld.2019.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
37 Dai Q, Liu T, Gao Y, Zhou H, Li X, Zhang W. Six genes involved in prognosis of hepatocellular carcinoma identified by Cox hazard regression. BMC Bioinformatics 2021;22:167. [PMID: 33784984 DOI: 10.1186/s12859-021-04095-7] [Reference Citation Analysis]
38 Guo D, Ma D, Liu P, Lan J, Liu Z, Liu Q. DNASE1L3 arrests tumor angiogenesis by impairing the senescence-associated secretory phenotype in response to stress. Aging (Albany NY) 2021;13:9874-99. [PMID: 33744849 DOI: 10.18632/aging.202740] [Reference Citation Analysis]
39 Da Fonseca LG, Reig M, Bruix J. Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success. Oncotarget 2018;9:33741-2. [PMID: 30333905 DOI: 10.18632/oncotarget.26052] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Ma XL, Shen MN, Hu B, Wang BL, Yang WJ, Lv LH, Wang H, Zhou Y, Jin AL, Sun YF, Zhang CY, Qiu SJ, Pan BS, Zhou J, Fan J, Yang XR, Guo W. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis. J Hematol Oncol 2019;12:37. [PMID: 30971294 DOI: 10.1186/s13045-019-0724-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 14.3] [Reference Citation Analysis]